Condition: Thyroid Nodule · Thyroid Goiter · Ablation · Sponsor: Pulse Biosciences, Inc.
The primary objective of this study is to reproduce in a multi-center study results obtained during the feasibility First-In-Human (FIH) study with Prof. Stefano Spiezia, MD (Ospedale del Mare, Naples, Italy) and to monitor additional thyroid-related symptoms and impact of patients quality of life post-ablation using a validated QoL questionnaire.
This description comes directly from the study's public registry record.
Ioana Gruchevska · (314) 484-7033 · ioana.gruchevska@pulsebiosciences.com
William A. Knape · 9197572033 · bknape@pulsebiosciences.com
Always discuss trial participation with your own doctor first.
| Sarasota Memorial Hospital | Sarasota, Florida, United States | Recruiting |
| NYU Langone Health | New York, New York, United States | Recruiting |
| Weill Cornell Medicine | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07287176